Cover Image
Market Research Report
Product code 
1091440

Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change

Published: | The Business Research Company | 263 Pages | Delivery time: 2-3 business days

Price

Back to Top
Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change
Published: June 17, 2022
The Business Research Company
Content info: 263 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

“Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change” from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global biosimilars market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? “The biosimilars market global report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider biosimilars market; and compares it with other markets.

The report covers the following chapters:

  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by product, segmentation by type and segmentation by application.
  • Market Characteristics - The market characteristics section of the report defines and explains the biosimilars market. This chapter also defines and describes goods and related services covered in the report.
  • Trends And Strategies - This chapter describes the major trends shaping the global biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact of COVID-19 - This section describes the impact of COVID-19 on the biosimilars market.
  • Global Market Size And Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
  • Global Macro Comparison - The global biosimilars market comparison with macro-economic factors gives the biosimilars market size, percentage of GDP, and average biosimilars market expenditure.
  • Regional Market Size and Growth - This section contains the region's market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global biosimilars market, estimated market shares and company profiles for the leading players.
  • Key Mergers And Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for biosimilars companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

  • 1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormone; Others
  • 2) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Others
  • Companies Mentioned: Amgen; Pfizer; Novartis AG; Viatris; Celltrion, Inc.
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; biosimilars indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary

This report describes and evaluates the global biosimilars market. It covers three five-year periods: 2015-2020, the historic period, and the forecast periods: 2020-2025 and 2025-2030. The report evaluates the market across each region as well as the major economies within each region.

The global biosimilars market reached a value of nearly $9,792.0 million in 2020, having increased at a compound annual growth rate (CAGR) of 43.5% since 2015. The market is expected to grow from $9,792.0 million in 2020 to $22,213.7 million in 2025 at a rate of 17.8%. The market is then expected to grow at a CAGR of 17.5% from 2025 and reach $49,786.4 million in 2030.

Growth in the historic period in the biosimilars market resulted from increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increased healthcare expenditure, government initiatives, strong pipeline of drugs, low cost of biosimilars, increase in patent expiration. The market was restrained by pricing pressures from regulators, challenges due to regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists and reimbursement challenges.

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of the biosimilar drugs, rising aging population, and increase in healthcare access will drive the growth in the vaccines market. Factors that could hinder the growth of the market in the future include high costs of drugs, high cost of drug development with threat of failure, and coronavirus pandemic.

The biosimilars market is segmented by type into monoclonal antibodies, insulin, erythropoietin, granulocyte-colony stimulating factor, other hormones and others. The monoclonal antibodies segment was the largest segment of the biosimilars market segmented by type, accounting for 35.9% of the total in 2020. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 26.5% during 2020-2025.

The biosimilars market is also segmented by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The chronic and autoimmune diseases segment was the largest segment of the biosimilars market segmented by application, accounting for 47.1% of the total in 2020. Going forward, the infectious diseases segment is expected to be the fastest growing segment in the biosimilars market segmented by application, at a CAGR of 24.6% during 2020-2025.

Western Europe was the largest region in the biosimilars market, accounting for 71.06% of the total in 2020. It was followed by the North America, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the biosimilars market will be Middle East and Africa where growth will be at CAGRs of 131.8% and 119.7% respectively during 2020-2025. These will be followed by South America and Eastern Europe, where the markets are expected to register CAGRs of 117.7% and 106.4% respectively during 2020-2025.

The biosimilars market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for biosimilars, and has resulted in low usage of biosimilars. For instance, Amgen's reference product Neulasta® (the original syringe form) have been steadily losing market share since the covid-19 outbreak, Coherus Bioscience's Udenyca® has been steadily gaining marketshare, utilization of Neulasta's OnPro® on-body injector has been relatively steady and the other biosimilar products (Fulphila® and Ziextenzo®) have not yet gathered momentum .Due to worldwide lockdown, production is also being halted which is causing supply chain issues.

The biosimilars market is highly consolidated with a small number of global players dominating the market. The key players in the market are focusing on expanding their operational and business presence in the biosimilars market through development of advanced technologies, strategic collaborations and acquisition and new product launch to meet the global demand. The top ten competitors in the market made up to 73.53% of the total market in 2020.

The top opportunities in the biosimilars market segmented by type will arise in monoclonal antibodies segment, which will gain $7,305.0 million of global annual sales by 2025. The top opportunities in the biosimilars market segmented by application will arise in oncology segment, which will gain $5,922.2 million of global annual sales by 2025. The biosimilars market size will gain the most in the USA at $5,575.5 million.

Market-trend-based strategies for the vaccines includes investing extensively in R&D activities for the development of effective and innovative drugs, efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings, M&A growth strategies to expand the customer base and their geographic markets, revised and less stringent regulations in practice, and establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments.

To take advantage of the opportunities, the business research company recommends the biosimilar companies to focus on robust research and development, on strategic partnerships for new product development, focus on biosimilars in the treatment of neutropenia, expand in emerging markets and in developed markets with high biosimilar adoption, set up authorized distributors and sales representatives, expand in countries offering research incentives, scale up through merger and acquisition activity, provide competitively priced offerings in low-income countries, direct marketing, focus on increasing awareness, targeting hospitals and pharmacies to spread awareness, focus on cancer patients and on the aging population.

Product Code: o&s422

Table of Contents

1. Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

  • 6.1. Segmentation By Geography
  • 6.2. Segmentation By Type
  • 6.3. Segmentation By Application

7. Biosimilars Market Characteristics

  • 7.1. Market Definition
  • 7.2. Segmentation By Type
    • 7.2.1. Monoclonal Antibodies
    • 7.2.2. Insulin
    • 7.2.3. Erythropoietin
    • 7.2.4. Granulocyte-Colony Stimulating Factor
    • 7.2.5. Other Hormone
    • 7.2.6. Others
  • 7.3. Segmentation By Application
    • 7.3.1. Oncology
    • 7.3.2. Chronic and Autoimmune Diseases
    • 7.3.3. Growth Hormone Deficiency
    • 7.3.4. Infectious Diseases
    • 7.3.5. Others

8. Biosimilars Market Trends And Strategies

  • 8.1. Robust Research & Development
  • 8.2. Demand For Biosimilars In The Treatment Of Neutropenia
  • 8.3. Growing Mergers And Acquisitions
  • 8.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development
  • 8.5. Large Number Of Strategic Partnerships
  • 8.6. Increasing Investments In Biosimilars Market

9. Impact Of COVID-19 On The Biosimilars Market

  • 9.1. Clinical Trial Delays
  • 9.2. Impact On Major Biosimilars Companies In The Market
  • 9.3. Impact On Rituximab Biosimilars
  • 9.4. How Leading Rituximab Biosimilars Companies Handled COVID
  • 9.5. Impact Of COVID-19 On Major Pegfilgrastim Biosimilar Market Player Biocon Biologics
  • 9.6. Future Outlook

10. Global Biosimilars Market Size And Growth

  • 10.1. Market Size
  • 10.2. Historic Market Growth, 2015 - 2020, Value ($ Million)
    • 10.2.1. Drivers Of The Market 2015 - 2020
    • 10.2.2. Restraints On The Market 2015 - 2020
  • 10.3.Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
    • 10.3.1. Drivers Of The Market 2020 - 2025
    • 10.3.2. Restraints On The Market 2020 - 2025

11. Global Biosimilars Market Segmentation

  • 11.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 11.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

12. Biosimilars Market, Regional And Country Analysis

  • 12.1. Global Biosimilars Market, By Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 12.2. Global Biosimilars Market, By Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Biosimilars Market

  • 13.1. Asia-Pacific Biosimilars Market Overview
    • 13.1.1. Region Information
    • 13.1.2. Market Information
    • 13.1.3. Background Information
    • 13.1.4. Government Initiatives
    • 13.1.5. Regulatory Bodies
    • 13.1.6. Regulations
    • 13.1.7. Major Associations
    • 13.1.8. Taxes Levied
    • 13.1.9. Corporate Tax Structure
    • 13.1.10. Investments
    • 13.1.11. Major Companies
  • 13.2. Asia-Pacific Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.3. Asia-Pacific Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.4.Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.5. Asia-Pacific Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.6.Asia-Pacific Biosimilars Market: Country Analysis
  • 13.7. China Biosimilars Market
  • 13.8.China Biosimilars Market Overview
    • 13.8.1. Country Information
    • 13.8.2. Market Information
    • 13.8.3. Background Information
    • 13.8.4. Government Initiatives
    • 13.8.5. Regulatory Bodies
    • 13.8.6. Regulations
    • 13.8.7. Major Associations
    • 13.8.8. Taxes Levied
    • 13.8.9. Corporate Tax Structure
    • 13.8.10. Investments
    • 13.8.11. Major Companies
  • 13.9.China Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.10. China Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.11. China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.12. China Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.13. India Biosimilars Market
  • 13.14. India Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.15. India Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.16. India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.17. India Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.18. Japan Biosimilars Market
  • 13.19. Japan Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.20. Japan Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.21. Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.22. Japan Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.23. Australia Biosimilars Market
  • 13.24. Australia Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.25. Australia Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.26. Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.27. Australia Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.28. Indonesia Biosimilars Market
  • 13.29. Indonesia Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.30. Indonesia Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.31. Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.32. Indonesia Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.33. South Korea Biosimilars Market
  • 13.34. South Korea Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 13.35. South Korea Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 13.36. South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 13.37. South Korea Biosimilars Market, Segmentation By Types, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

14. Western Europe Biosimilars Market

  • 14.1.Western Europe Biosimilars Market Overview
    • 14.1.1. Region Information
    • 14.1.2. Market Information
    • 14.1.3. Background Information
    • 14.1.4. Government Initiatives
    • 14.1.5. Regulatory Bodies
    • 14.1.6. Regulations
    • 14.1.7. Major Associations
    • 14.1.8. Taxes Levied
    • 14.1.9. Corporate Tax Structure
    • 14.1.10. Investments
    • 14.1.11. Major Companies
  • 14.2. Western Europe Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 14.3.Western Europe Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 14.4. Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.5. Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.6. Western Europe Biosimilars Market: Country Analysis
  • 14.7. UK Biosimilars Market
  • 14.8. UK Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 14.9. UK Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 14.10. UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.11. UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.12. Germany Biosimilars Market
  • 14.13. Germany Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 14.14. Germany Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 14.15. Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.16. Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.17. France Biosimilars Market
  • 14.18. France Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 14.19. France Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 14.20. France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 14.21. France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

15. Eastern Europe Biosimilars Market

  • 15.1. Eastern Europe Biosimilars Market Overview
    • 15.1.1. Region Information
    • 15.1.2. Market Information
    • 15.1.3. Background Information
    • 15.1.4. Government Initiatives
    • 15.1.5. Regulatory Bodies
    • 15.1.6. Regulations
    • 15.1.7. Taxes Levied
    • 15.1.8. Corporate Tax Structure
    • 15.1.9. Investments
    • 15.1.10. Major Companies
  • 15.2. Eastern Europe Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 15.3. Eastern Europe Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 15.4. Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 15.5. Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 15.6. Eastern Europe Biosimilars Market: Country Analysis
  • 15.7. Russia Biosimilars Market
  • 15.8. Russia Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 15.9. Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 15.10. Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

16. North America Biosimilars Market

  • 16.1.North America Biosimilars Market Overview
    • 16.1.1. Region Information
    • 16.1.2. Market Information
    • 16.1.3. Background Information
    • 16.1.4. Government Initiatives
    • 16.1.5. Regulatory Bodies
    • 16.1.6. Regulations
    • 16.1.7. Major Associations
    • 16.1.8. Taxes Levied
    • 16.1.9. Corporate tax structure
    • 16.1.10. Investments
    • 16.1.11. Major Companies
  • 16.2. North America Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 16.3.North America Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 16.4. North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 16.5. North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 16.6. North America Biosimilars Market: Country Analysis
  • 16.7. USA Biosimilars Market
  • 16.8. USA Biosimilars Market Overview
    • 16.8.1. Country Information
    • 16.8.2. Market Information
    • 16.8.3. Background Information
    • 16.8.4. Government Initiatives
    • 16.8.5. Regulatory Bodies
    • 16.8.6. Regulations
    • 16.8.7. Major Associations
    • 16.8.8. Taxes Levied
    • 16.8.9. Corporate Tax Structure
    • 16.8.10.Investments
    • 16.8.11. Major Companies
  • 16.9. USA Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 16.10. USA Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 16.11. USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 16.12. USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

17. South America Biosimilars Market

  • 17.1. South America Biosimilars Market Overview
    • 17.1.1. Region Information
    • 17.1.2. Market Information
    • 17.1.3. Background Information
    • 17.1.4. Government Initiatives
    • 17.1.5. Regulatory Bodies
    • 17.1.6. Regulations
    • 17.1.7. Major Associations
    • 17.1.8. Taxes Levied
    • 17.1.9. Corporate Tax Structure
    • 17.1.10. Investments
    • 17.1.11. Major Companies
  • 17.2. South America Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 17.3. South America Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 17.4. South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 17.5. South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 17.6. South America Biosimilars Market: Country Analysis
  • 17.7. Brazil Biosimilars Market
  • 17.8. Brazil Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 17.9. Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 17.10. Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

18. Middle East Biosimilars Market

  • 18.1. Middle East Biosimilars Market Overview
    • 18.1.1. Region Information
    • 18.1.2. Market Information
    • 18.1.3. Background information
    • 18.1.4. Government Initiatives
    • 18.1.5. Regulatory Bodies
    • 18.1.6. Regulations
    • 18.1.7. Major Associations
    • 18.1.8. Taxes Levied
    • 18.1.9. Corporate Tax Structure
    • 18.1.10. Investments
    • 18.1.11. Major Companies
  • 18.2. Middle East Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 18.3.Middle East Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 18.4. Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 18.5. Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

19. Africa Biosimilars Market

  • 19.1.Africa Biosimilars Market Overview
    • 19.1.1. Region Information
    • 19.1.2. Market Information
    • 19.1.3. Background information
    • 19.1.4. Government Initiatives
    • 19.1.5. Regulatory Bodies
    • 19.1.6. Regulations
    • 19.1.7. Major Associations
    • 19.1.8. Taxes Levied
    • 19.1.9. Corporate Tax Structure
    • 19.1.10. Investments
    • 19.1.11. Major Companies
  • 19.2. Africa Biosimilars Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
  • 19.3.Africa Biosimilars Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
  • 19.4. Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
  • 19.5. Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

20. Biosimilars Market Competitive Landscape

  • 20.1. Company Profiles
  • 20.2. Amgen Inc.
    • 20.2.1. Company Overview
    • 20.2.2. Products And Services
    • 20.2.3. Business Strategy
    • 20.2.4. Financial Overview
  • 20.3. Pfizer Inc.
    • 20.3.1. Company Overview
    • 20.3.2. Products And Services
    • 20.3.3. Business Strategy
    • 20.3.4. Financial Overview
  • 20.4. Novartis AG
    • 20.4.1. Company Overview
    • 20.4.2. Products And Services
    • 20.4.3. Business Strategy
    • 20.4.4. Financial Overview
  • 20.5. Viatris Inc.
    • 20.5.1. Company Overview
    • 20.5.2. Products And Services
    • 20.5.3. Business Strategy
    • 20.5.4. Financial Overview
  • 20.6. Celltrion, Inc.
    • 20.6.1. Company Overview
    • 20.6.2. Products And Services
    • 20.6.3. Business Strategy
    • 20.6.4. Financial Overview

21. Key Mergers And Acquisitions In The Biosimilars Market

  • 21.1. Celltrion Acquired Takeda Pharmaceuticals
  • 21.2. ChrysCapital Acquired Stakes In Intas Pharmaceuticals
  • 21.3. Amgen Acquired Japanese JV with Astellas
  • 21.4. True North Acquired Stake In Biocon Biologics Ltd.
  • 21.5. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.
  • 21.6. Pfizer Inc. Acquired Array BioPharma Inc.
  • 21.7. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital
  • 21.8. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech
  • 21.9. Kashiv Pharma Acquired Adello Biologics
  • 21.10. Bristol-Myers Squibb Acquired Celgene Corporation
  • 21.11. Takeda Pharmaceutical Company Limited Acquired Shire Plc
  • 21.12. Amneal Pharmaceuticals Merge With Impax Laboratories
  • 21.13. Biocon Merged With Sandoz
  • 21.14. Sun Pharmaceutical Industries Limited Acquired Zenotech Laboratories

22. Biosimilars Market Opportunities And Strategies

  • 22.1. Global Biosimilars Market In 2025 - Countries Offering Most New Opportunities
  • 22.2. Global Biosimilars Market In 2025 - Segments Offering Most New Opportunities
  • 22.3. Global Biosimilars Market In 2025 - Growth Strategies
    • 22.3.1. Market Trend Based Strategies
    • 22.3.2. Competitor Strategies

23. Biosimilars Market, Conclusions And Recommendations

  • 23.1. Conclusions
  • 23.2. Recommendations
    • 23.2.1. Product
    • 23.2.2. Place
    • 23.2.3. Price
    • 23.2.4. Promotion
    • 23.2.5. People

24. Appendix

  • 24.1. Market Data Sources
  • 24.2. Research Methodology
  • 24.3. Currencies
  • 24.4. Research Inquiries
  • 24.5. The Business Research Company
  • 24.6. Copyright and Disclaimer